Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Open Label Study to Assess the Safety and Pharmacokinetics of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Agents Used in Colorectal Cancer Treatment

Trial Profile

A Phase Ib Open Label Study to Assess the Safety and Pharmacokinetics of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Agents Used in Colorectal Cancer Treatment

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2019

At a glance

  • Drugs Bevacizumab (Primary) ; Cetuximab (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; NUC 3373 (Primary) ; Oxaliplatin (Primary) ; Panitumumab (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Acronyms NuTide:302
  • Sponsors NuCana
  • Most Recent Events

    • 01 Dec 2018 According to a NuCana media release, first patient has been enrolled.
    • 01 Oct 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Sep 2018 to 1 Oct 2018.
    • 01 Oct 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top